壮方柔肝化纤颗粒治疗肝肾阴虚型乙肝肝硬化腹水的效果

摘要
图/表
参考文献(25)
相关文章 (2)

全文: PDF (756 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察壮方柔肝化纤颗粒治疗肝肾阴虚型乙肝肝硬化腹水的效果。方法选取2017年2月～2019年2月于广西中医药大学第一附属医院及广西国际壮医医院肝病科确诊为肝肾阴虚型乙肝肝硬化腹水患者70例，按随机数字表法将其分为对照组和观察组，每组35例。对照组采取内科常规治疗，观察组在对照组的基础上采用壮方柔肝化纤颗粒。比较两组治疗后的总有效率及治疗前后的中医证候积分、肝功能指标、体重、腹围及24 h尿量。结果观察组的临床总有效率高于对照组，差异有统计学意义（P < 0.05）。两组治疗后的黄疸、食欲减退、腹胀腹泻、肝脾肿大积分均低于治疗前，且观察组低于对照组，差异有统计学意义（P < 0.05）。两组治疗后的谷草转氨酶、谷丙转氨酶、总胆红素水平均低于治疗前，白蛋白水平高于治疗前，且观察组改善较对照组显著，差异有统计学意义（P < 0.05）。与治疗前比较，两组治疗后体重降低，腹围减小，24 h尿量增加，且观察组改善较对照组显著，差异有统计学意义（P ＜ 0.05）。结论壮方柔肝化纤颗粒治疗肝肾阴虚型乙肝肝硬化腹水能明显提高患者的治疗效果，改善肝功能及生存质量，值得借鉴。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴姗姗1 吕艳杭1 王振常2▲ 符燕青1 陈美岑1 吕黄华1

关键词 ：壮医药, 柔肝化纤颗粒, 乙肝肝硬化腹水, 肝肾阴虚证

Abstract：Objective To observe effect of Zhuangfang Ruogan Huaxian Granules in the treatment of ascites due to hepatitis B cirrhosis with syndrome of liver-kidney yin deficiency. Methods From February 2017 to February 2019, 70 patients with hepatitis B cirrhosis ascites with syndrome of liver-kidney yin deficiency were selected from the First Affiliated Hospital of Guangxi University of Chinese Medicine and Hepatology Department of Guangxi International Zhuang Medical Hospital. They were divided into control group and observation group according to the random number table method, with 35 cases in each group. Control group received routine medical treatment, while observation group received Zhuangfang Ruogan Huaxian Granule on the basis of control group. Total effective rate after treatment, traditional Chinese medicine syndrome score, liver function index, body mass, abdominal circumference and 24 h urine volume before and after treatment were compared between two groups. Results Total clinical effective rate of observation group was higher than that of control group (P < 0.05). The scores of jaundice, anorexia, abdominal distention, diarrhea, hepatosplenomegaly in two groups after treatment were lower than those before treatment, observation group was lower than control group, and the differences were statistically significant (P < 0.05). The levels of AST, ALT and TBIL in two groups after treatment were lower than those before treatment, and the level of ALB in observation group after treatment was higher than that before treatment, and the improvement in observation group was more significant than that in control group, and the differences were statistically significant (P < 0.05). Compared with those before treatment, body mass in the two groups decreased, abdominal circumference reduced, and 24 h urine volume increased after treatment, and the improvement in observation group was more significant than that in control group, and the differences were statistically significant (P < 0.05). Conclusion Zhuangfang Ruogan Huaxian Granules can obviously improve the therapeutic effect and improve the liver function and quality of life of patients with ascites due to hepatitis B cirrhosis with syndrome of liver-kidney yin deficiency.

Key words： Zhuang medicine Rougan Huaxian Granules Ascites due to hepatitis B cirrhosis Syndrome of liver-kidney yin deficiency

基金资助:国家自然科学基金资助项目（81660745）。

通讯作者: ▲通讯作者

引用本文:

吴姗姗1 吕艳杭1 王振常2▲ 符燕青1 陈美岑1 吕黄华1. 壮方柔肝化纤颗粒治疗肝肾阴虚型乙肝肝硬化腹水的效果[J]. 中国医药导报, 2020, 17(1): 122-125.
WU Shanshan1 LYU Yanhang1 WANG Zhenchang2▲ FU Yanqing1 CHEN Meicen1 LYU Huanghua1. Effect of Zhuangfang Ruogan Huaxian Granules in the treatment of ascites due to hepatitis B cirrhosis with syndrome of liver-kidney yin deficiency. 中国医药导报, 2020, 17(1): 122-125.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I1/122

[1] Kim TH，Ku DH，Um SH，et al. How can we improve the performance of model for end-stage liver disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment? [J]. J Gastroenterol Hepatol，2018，33（9）：1641-1648.
[2] Huang J. Evaluation of infection in patients with chronic hepatic disease [J]. Chin Med J，2017，130（2）：149-154.
[3] 王贵强.慢性乙型肝炎防治指南（2015年版）[J].实用肝脏病杂志，2016，19（3）：389-400．
[4] 中华中医药学会脾胃病分会，张声生，王宪波.肝硬化腹水中医诊疗专家共识意见（2017）[J].中华中医药杂志，2017，32（7）：3065-3068.
[5] 国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，1994.
[6] Chen C，Chen DP，Gu YY，et al. Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis：possible associations with ascites and hepatitis B viral factors? [J]. Tumour Biol，2015，36（8）：6255-6263.
[7] Zhang X，Wang SZ，Zheng JF，et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients [J]. World J Gastroenterol，2014，20（32）：11400-11405.
[8] Yue-Meng W，Li YH，Wu HM，et al. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt：risk factors，warfarin efficacy，and clinical outcomes [J]. Clin Appl Thromb Hemost，2018，24（3）：462-470.
[9] 胡大山，胡建强，刘欢，等.肝硬化腹水患者的临床特征新趋势[J].肝脏，2019，24（2）：181-184.
[10] 苏洪佳，陈国忠，谢君艳.从中医脾虚“不能散精”论治肝硬化腹水[J].辽宁中医杂志，2019，46（1）：61-62.
[11] 崔璀，张志勇，薛敬东.一贯煎合猪苓汤联合西药治疗肝肾阴虚型肝硬化腹水临床观察[J].新中医，2017，49（2）：51-54.
[12] 李自强.养阴利水法治疗肝肾阴虚型顽固性肝硬化腹水32例[J].陕西中医，2009，30（9）：1119-1120.
[13] Wang C，Yang S，Huang J，et al. Activation of corticotropin releasing factor receptors up regulates collagen production by hepatic stellate cells via promoting p300 expression [J]. Biol Chem，2016，397（5）：437-444.
[14] 王振常，朱智德，杨删，等.柔肝化纤颗粒对肝纤维化大鼠ACTA表达的影响[J].时珍国医国药，2012，23（11）：2705-2707.
[15] 黄晶晶，黄鸿娜，王振常，等.柔肝化纤方联合腹水超滤浓缩回输术治疗肝硬化腹水40例临床观察[J].河北中医，2014，36（10）：1492-1495.
[16] 王露，陈英杰，彭立生，等.麝黄膏敷脐联合中药口服辅助治疗肝硬化腹水的临床效果[J].世界中医药，2018， 13（2）：352-355.
[17] 吴华清，孙晓伟，王焕英，等.消瘀降浊汤治疗瘀血阻滞证肝硬化腹水的疗效观察[J].中国现代医生，2017，55（3）：113-116.
[18] 付世阳.一贯煎加味治疗肝硬化腹水（肝肾阴虚证）的临床观察[D].长春：长春中医药大学，2014.
[19] 甘大楠，杜宏波，池晓玲，等.自拟益气活血方治疗乙肝肝硬化腹水气虚血瘀证临床疗效与安全性研究[J].世界中医药，2018，13（12）：2980-2986.
[20] 张兴会.杞地软坚消臌汤加服醋甘遂胶囊治疗肝肾阴虚型肝硬化腹水26例[J].中西医结合肝病杂志，2013，23（5）：305-306.
[21] 魏莹莹.肝硬化自发性细菌性腹膜炎预后分析及中医证型与相关指标的研究[D].北京：北京中医药大学，2018.
[22] 张静，曹艳丽.中西医结合治疗肝肾阴虚型病毒性肝硬化腹水[J].光明中医，2013，28（2）：342-343.
[23] 徐佳娜.五苓散加减治疗乙肝肝硬化腹水临床疗效分析[J].中国医药科学，2018，8（17）：86-88，100.
[24] Wang Z，Li Q，Xiang M，et al. Astragaloside alleviates hepatic fibrosis function via Par2 signaling pathway in diabetic rats [J]. Cell Physiol Biochem，2017，41（3）：1156-1166.
[25] Wang ZC，Yang S，Huang JJ，et al. Effect of bone marrow mesenchymal stem cells on the Smad expression of hepatic fibrosis rats [J]. Asian Pac J Trop Med，2014，7（4）：321-324.